in this issue
EnviroTech :: Regulatory
New U.S. Biosimilars Bill Gets Mixed Reviews
10:26 AM MDT | April 7, 2008 | Deepti Ramesh
A new House bill on biosimilars is drawing mixed reviews from industry. The Generic Pharmaceutical Association (GPhA; Arlington, VA) calls the Pathway for Biologics Act “a step backward” that puts brand company profits before patient needs, but the Biotechnology Industry Organization (BIO; Washington) says the bill is an important step forward toward follow-on biologics. Representatives Anna Eshoo (D., CA) and Joe Barton (R., TX) introduced the bill last month. Eshoo: Pathway to promote innovation. The bill provides 12 years of data exclusivity for...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee